GILD vs MRK
GILD: A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis, and cancer. MRK: Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda.
Side-by-side fundamentals
| Metric | GILD | MRK | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $134.84 | $125.07 | |
| Market cap as of 2026-07-10 | $166.0B | $310.1B | |
| P/E as of 2026-07-10 | 18.01 | 34.71 | GILD lower |
| PEG as of 2026-07-10 | 1.94 | 4.34 | GILD lower |
| Net margin as of 2026-07-10 | +31.0% | +13.6% | GILD higher |
| Gross margin as of 2026-07-10 | +79.3% | +78.1% | GILD higher |
| Operating margin as of 2026-07-10 | +34.9% | +18.2% | GILD higher |
| ROE as of 2026-07-10 | +42.2% | +17.9% | GILD higher |
| ROA as of 2026-07-10 | +16.1% | +7.0% | GILD higher |
| Debt / equity as of 2026-07-10 | 0.94 | 1.07 | GILD lower |
| Revenue growth (YoY) as of 2026-07-10 | +3.5% | +2.9% | GILD higher |
| Revenue CAGR (3y) SEC XBRL | +2.6% | +3.1% | MRK higher |
| Dividend yield as of 2026-07-10 | +2.4% | +2.7% | MRK higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-10 | 0.34 | 0.21 | |
| 1-year return as of 2026-07-09 close | +19.1% | +49.4% | MRK higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.